Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Almost a third of people with major depressive disorder find that regular treatments, including anti-depressant drugs, or even electroconvulsive therapy, don't help. Now, a new year-long trial of a ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...